Tirzepatide 40mg Bulk Sales USA

Tirzepatide 40mg Bulk Sales USA — Comprehensive Product Overview Tirzepatide 40 mg is a bulk-format, research-grade dual GIP/GLP-1 receptor agonist peptide engineered specifically for high-volume research programs, multi-investigator collaborative studies, contract research organization (CRO) projects, and pharmaceutical discovery platforms requiring substantial quantities of analytically verified Tirzepatide for large-scale preclinical investigations. As the entry point to our bulk Tirzepatide portfolio, the 40 mg format delivers significant economies of scale for research programs that have validated their experimental protocols and are scaling to larger cohorts, longer treatment durations, or higher-throughput screening formats. Tirzepatide (CAS: 2023788-19-2, MW: 4813.5 Da) is the 39-amino acid synthetic peptide amide whose dual-receptor pharmacology has redefined incretin research. The molecular design — H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 — integrates three critical pharmacological innovations: (1) Aib residues at positions 2 and 13 that confer DPP-4 resistance by stabilizing the N-terminal α-helical conformation essential for receptor binding while blocking protease access; (2) a C20 eicosanedioic acid moiety conjugated at Lys20 through a dual AEEA-γ-Glu linker that provides the high-affinity reversible albumin binding (≥99.5% bound) responsible for the extended pharmacokinetic half-life enabling once-daily or thrice-weekly dosing in rodent models and once-weekly exposure in larger species; and (3) an imbalanced dual agonism profile (5-fold GIPR super-agonism, balanced GLP-1R agonism) that produces synergistic metabolic effects exceeding what either receptor pathway alone can achieve. The 40 mg bulk format is designed for research programs that have moved beyond pilot and validation phases into production-scale experimentation. This quantity supports: large rodent cohorts (20-40 animals) for adequately powered metabolic phenotyping studies; chronic treatment paradigms extending beyond 8 weeks for investigations of long-term metabolic adaptation; multi-site collaborative studies where a single, analytically verified lot ensures consistency across participating laboratories; high-throughput screening campaigns utilizing cell-based assay platforms; and comprehensive dose-response studies with multiple treatment arms across wide concentration ranges. Each vial is produced under GMP-aligned quality systems with rigorous batch testing (HPLC purity, mass spectrometry, amino acid analysis, endotoxin quantification, and residual solvent analysis) and complete lot traceability. Supplied strictly for research use only (RUO). Key Features 40 mg bulk research vial — the cost-effective entry point for high-volume research programs and large-scale preclinical studies Dual GIP and GLP-1 receptor agonist — synergistic dual-incretin mechanism for comprehensive metabolic, endocrine, and neurological research ≥99% HPLC purity — every bulk batch analytically verified with complete documentation; bulk quantity does not mean compromised quality Lyophilized powder for extended stability — 24+ month shelf life at -20°C; bulk vials maintain purity specifications throughout storage period DPP-4-resistant peptide backbone — Aib residues ensure sustained bioactivity across chronic dosing paradigms Albumin-binding pharmacokinetic optimization — C20 diacid moiety enables flexible dosing schedules in preclinical models Bulk-optimized packaging — professional laboratory-grade packaging designed for frequent access without compromising sterility or stability Ideal for large-cohort chronic studies, multi-site collaborations, CRO projects, and pharmaceutical screening platforms Volume pricing and institutional supply agreements available The Science of Tirzepatide: Why Bulk Quantities Matter for Research Reproducibility For research programs operating at scale, the scientific rationale for bulk Tirzepatide extends beyond simple economics. Lot-to-lot variability — even within the tight specifications of ≥99% HPLC purity — can introduce subtle differences in peptide content, residual moisture, counter-ion composition, and trace impurities that, while individually within specification, may collectively influence experimental outcomes when different lots are used across experimental phases. By providing sufficient material from a single, analytically homogeneous production lot, the 40 mg bulk format eliminates lot-to-lot variability as a confounding variable in large-scale or longitudinal studies. This is particularly critical for: chronic dosing studies where animals initiated on one lot and switched to another mid-study create uncontrolled variables; multi-site collaborations where inter-laboratory variability is already a concern and peptide lot differences add another dimension of uncertainty; dose-response studies where apparent potency differences between concentration levels could reflect lot differences rather than true pharmacological gradients; and replication studies where exact experimental conditions must be reproduced to validate previous findings. Furthermore, the bulk format enables comprehensive in-study quality control: researchers can retain aliquots for post-hoc analytical verification, conduct stability testing under their specific storage and handling conditions, and perform independent purity and bioactivity assessments — all from the same lot used in the primary experiments. This level of quality assurance is essential for research intended for regulatory submission, patent filing, or high-impact publication. Research Applications Tirzepatide 40 mg is optimized for: Large-cohort chronic in vivo studies — 8-12 week treatment paradigms in 20-40 DIO mice or 10-20 ZDF rats with comprehensive metabolic phenotyping at multiple time points; Multi-arm preclinical efficacy studies — vehicle, multiple Tirzepatide dose levels, Semaglutide comparator, Retatrutide comparator, and combination arms from a single analytically verified lot; High-throughput in vitro screening — cell-based cAMP, β-arrestin, insulin secretion, and metabolic flux assays across thousands of wells using automated liquid handling platforms; Multi-site collaborative research — distributing aliquots of a single production lot across collaborating laboratories to ensure pharmacological consistency; Long-term metabolic adaptation studies — investigating the durability of Tirzepatide effects on body weight, glycemic control, and tissue metabolism over 12-16 week treatment periods; Comprehensive tissue bank generation — terminal studies producing matched tissue sets (liver, adipose depots, skeletal muscle, pancreas, brain regions, heart, kidney) for multi-omics analyses (transcriptomics, proteomics, metabolomics, lipidomics); CRO and pharmaceutical discovery programs — supporting IND-enabling preclinical pharmacology, toxicology, and pharmacokinetic studies. Comparative Analysis: Tirzepatide vs. Semaglutide vs. Retatrutide at Scale In large-scale research programs, the pharmacological distinctions between incretin peptides have operational and budgetary implications: Semaglutide — as the most established GLP-1R agonist, Semaglutide benefits from extensive literature precedent, well-characterized dosing paradigms, and widespread availability. It remains the essential GLP-1R-selective control in all incretin research programs. However, its single-receptor mechanism means that research programs investigating GIP biology or GIP-GLP-1 synergy must supplement with Tirzepatide, effectively doubling peptide requirements. Tirzepatide — the dual mechanism provides experimental access to both GLP-1R and GIPR biology in a single compound, potentially reducing the number of treatment arms needed to characterize incretin effects. In large-scale programs, this consolidation can significantly reduce total peptide costs while increasing experimental throughput. The 40 mg bulk format amplifies these economies of scale. Retatrutide — the triple agonist mechanism introduces GCGR pharmacology that may be scientifically desirable for specific research questions but adds complexity to large-scale study designs (additional endpoints for hepatic function, amino acid metabolism, and α-cell biology). For programs primarily focused on the GIP-GLP-1 axis, Tirzepatide provides a more focused, cost-effective tool. Disclaimer This product is intended exclusively for laboratory research purposes only. Not FDA-approved for human or veterinary clinical, diagnostic, or therapeutic use. Purchasers must be qualified researchers at recognized institutions. Use only for legitimate scientific research in compliance with all applicable laws, regulations, and institutional guidelines. Product Specifications Product Name: Tirzepatide CAS Number: 2023788-19-2 Molecular Formula: C225H348N48O68 Molecular Weight: 4813.5 Da Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Purity: ≥99% (HPLC, 214 nm) Strength: 40 mg per vial Form: Sterile lyophilized powder Grade: Research Use Only (RUO) Solubility: PBS (pH 7.4), 0.1% acetic acid, DMSO, DMF Storage: Lyophilized: -20°C, desiccated; Reconstituted: aliquot, -20°C or -80°C, avoid freeze-thaw Quality Assurance & Analytical Testing HPLC (214 nm) — ≥99%; ESI-MS — MW ±1.0 Da; AAA — compositional verification; Peptide Content — mass/vial accuracy; Endotoxin (LAL) — quantified; Residual Solvents (GC-HS) — ICH Q3C; Appearance/Solubility/pH — verified; CoA available upon request. Handling & Storage Guidelines Lyophilized: -20°C, 24+ months; Reconstitution: sterile PBS pH 7.4; Post-reconstitution: aliquot single-use, -20°C (4 weeks) or -80°C (6 months); Working solutions: fresh daily from frozen aliquots; Bulk access: minimize vial opening frequency; consider aliquoting lyophilized powder under inert atmosphere for programs requiring frequent small-quantity access. USA Shipping & Availability Fast USA domestic shipping; Cold-chain insulated packaging; Professional discreet packaging; Available to qualified US institutions; International shipping for qualified institutions; Bulk/wholesale pricing and institutional supply agreements — contact sales for customized quotes. Why Choose Our Tirzepatide 40 mg Bulk? Economies of scale for high-volume research programs — lower per-mg cost compared to smaller formats; Single-lot consistency across large studies — eliminates lot-to-lot variability; ≥99% HPLC purity maintained in bulk format; Dual GIP/GLP-1 mechanism for comprehensive incretin research; Complete analytical documentation with batch-specific CoA; Bulk-optimized packaging for frequent laboratory access; Institutional supply agreements and scheduled delivery options available; Trusted by US academic cores, CROs, and pharmaceutical discovery groups. Advantages and Limitations Advantages: Cost-effective bulk format for large-scale research; Single-lot homogeneity across extended studies; Sufficient for large cohorts (20-40 animals, 8-12 weeks); Supports multi-arm, multi-site, and high-throughput experimental designs; Comprehensive analytical documentation. Limitations: Not for clinical/therapeutic use; Requires IACUC approval for in vivo work; Bulk format requires careful storage management and aliquot planning; For very large programs, contact us about custom synthesis and even larger bulk quantities. Frequently Asked Questions (FAQs) Q: FDA-approved? A: No. Research use only. Q: Who can purchase? A: Qualified researchers at accredited institutions; institutional verification required for bulk orders. Q: USA shipping? A: Yes, fast domestic shipping. Q: What makes this a “bulk” format? A: 40 mg quantity with volume pricing — the entry point for high-volume research programs. Q: Is purity compromised in bulk format? A: No. Same ≥99% HPLC specification as all Tirzepatide products. Q: vs. Semaglutide? A: Dual GIP/GLP-1 vs. GLP-1R-only; Tirzepatide captures both incretin pathways. Q: Storage? A: -20°C lyophilized; aliquoted reconstituted at -20°C/-80°C. Q: Shelf life? A: 24+ months lyophilized. Q: Institutional supply agreements? A: Yes, contact sales for recurring delivery and custom pricing. Q: CoA? A: Batch-specific CoA available upon request. Ordering Information Visit hkpeptidesworldwide.com to order. For bulk pricing, institutional supply agreements, and large-volume quotes, contact our scientific sales team directly. Purchase orders, credit cards, and wire transfers accepted. HK Peptides Worldwide — your bulk Tirzepatide supplier for large-scale research.

Related Research & Resources

Resource	Description
Glp 1 Metabolic Peptides Hub	Complete research overview & methodology hub
High Purity Tirzepatide 50Mg	Related research peptide product
Tirzepatide 10 Mg Research Peptide Vials	Related research peptide product
Glp 1 Peptides Metabolic Research	Latest research insights & methodology

View Complete Research Guide »